A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 23 08 2019
accepted: 11 09 2019
pubmed: 15 10 2019
medline: 20 3 2020
entrez: 15 10 2019
Statut: ppublish

Résumé

Huntington disease (HD) is caused by an unstable CAG/CAA repeat expansion encoding a toxic polyglutamine tract. Here, we tested the hypotheses that HD outcomes are impacted by somatic expansion of, and polymorphisms within, the HTT CAG/CAA glutamine-encoding repeat, and DNA repair genes. The sequence of the glutamine-encoding repeat and the proportion of somatic CAG expansions in blood DNA from participants inheriting 40 to 50 CAG repeats within the TRACK-HD and Enroll-HD cohorts were determined using high-throughput ultra-deep-sequencing. Candidate gene polymorphisms were genotyped using kompetitive allele-specific PCR (KASP). Genotypic associations were assessed using time-to-event and regression analyses. Using data from 203 TRACK-HD and 531 Enroll-HD participants, we show that individuals with higher blood DNA somatic CAG repeat expansion scores have worse HD outcomes: a one-unit increase in somatic expansion score was associated with a Cox hazard ratio for motor onset of 3·05 (95% CI = 1·94 to 4·80, p = 1·3 × 10 These data establish pure CAG length, rather than encoded-glutamine, as the key inherited determinant of downstream pathophysiology. These findings have implications for HD diagnostics, and support somatic expansion as a mechanistic link for genetic modifiers of clinical outcomes, a driver of disease, and potential therapeutic target in HD and related repeat expansion disorders. CHDI Foundation.

Sections du résumé

BACKGROUND BACKGROUND
Huntington disease (HD) is caused by an unstable CAG/CAA repeat expansion encoding a toxic polyglutamine tract. Here, we tested the hypotheses that HD outcomes are impacted by somatic expansion of, and polymorphisms within, the HTT CAG/CAA glutamine-encoding repeat, and DNA repair genes.
METHODS METHODS
The sequence of the glutamine-encoding repeat and the proportion of somatic CAG expansions in blood DNA from participants inheriting 40 to 50 CAG repeats within the TRACK-HD and Enroll-HD cohorts were determined using high-throughput ultra-deep-sequencing. Candidate gene polymorphisms were genotyped using kompetitive allele-specific PCR (KASP). Genotypic associations were assessed using time-to-event and regression analyses.
FINDINGS RESULTS
Using data from 203 TRACK-HD and 531 Enroll-HD participants, we show that individuals with higher blood DNA somatic CAG repeat expansion scores have worse HD outcomes: a one-unit increase in somatic expansion score was associated with a Cox hazard ratio for motor onset of 3·05 (95% CI = 1·94 to 4·80, p = 1·3 × 10
INTERPRETATION CONCLUSIONS
These data establish pure CAG length, rather than encoded-glutamine, as the key inherited determinant of downstream pathophysiology. These findings have implications for HD diagnostics, and support somatic expansion as a mechanistic link for genetic modifiers of clinical outcomes, a driver of disease, and potential therapeutic target in HD and related repeat expansion disorders.
FUNDING BACKGROUND
CHDI Foundation.

Identifiants

pubmed: 31607598
pii: S2352-3964(19)30624-3
doi: 10.1016/j.ebiom.2019.09.020
pmc: PMC6838430
pii:
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

568-580

Subventions

Organisme : Wellcome Trust
ID : 200181/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Hum Mol Genet. 2009 Aug 15;18(16):3039-47
pubmed: 19465745
Cell. 2015 Jul 30;162(3):516-26
pubmed: 26232222
Lancet Neurol. 2018 Nov;17(11):986-993
pubmed: 30243861
DNA Repair (Amst). 2007 Jun 1;6(6):789-96
pubmed: 17293170
Hum Mol Genet. 2003 Dec 15;12(24):3359-67
pubmed: 14570710
Clin Genet. 2009 Mar;75(3):244-50
pubmed: 19250382
Lancet Neurol. 2017 Sep;16(9):701-711
pubmed: 28642124
Hum Mol Genet. 2007 May 15;16(10):1133-42
pubmed: 17409200
Trends Genet. 2018 Jun;34(6):448-465
pubmed: 29567336
Lancet Neurol. 2013 Jul;12(7):637-49
pubmed: 23664844
Hum Mol Genet. 1995 Sep;4(9):1519-26
pubmed: 8541834
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3467-72
pubmed: 18299573
Neurology. 2016 Jul 19;87(3):282-8
pubmed: 27335115
Nat Neurosci. 2015 Jun;18(6):807-16
pubmed: 25938884
Hum Mol Genet. 2019 Feb 15;28(4):650-661
pubmed: 30358836
Mov Disord. 1996 Mar;11(2):136-42
pubmed: 8684382
Nat Commun. 2013;4:1511
pubmed: 23443539
J Med Genet. 1999 Jul;36(7):546-8
pubmed: 10424816
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Mov Disord Clin Pract. 2016 Jun 22;4(2):212-224
pubmed: 30363395
Am J Med Genet A. 2018 Apr;176(4):842-861
pubmed: 29218782
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Neuron. 2015 Nov 18;88(4):667-77
pubmed: 26590344
J Oncol. 2018 Apr 23;2018:3979135
pubmed: 29849630
Eur J Hum Genet. 2013 May;21(5):480-6
pubmed: 22990145
Cell. 2019 Aug 8;178(4):887-900.e14
pubmed: 31398342
Am J Hum Genet. 2019 Jun 6;104(6):1116-1126
pubmed: 31104771
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80
pubmed: 18096682
Eur Neurol. 2006;55(4):189-92
pubmed: 16772714
Biochemistry. 2013 Nov 19;52(46):8219-25
pubmed: 24199621
Sci Rep. 2017 May 2;7(1):1307
pubmed: 28465506
Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408
pubmed: 19548255
Brain Pathol. 2016 Nov;26(6):779-786
pubmed: 27529325

Auteurs

Marc Ciosi (M)

Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Alastair Maxwell (A)

Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Sarah A Cumming (SA)

Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Davina J Hensman Moss (DJ)

Huntington's Disease Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.

Asma M Alshammari (AM)

Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Michael D Flower (MD)

Huntington's Disease Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.

Alexandra Durr (A)

APHP Department of Genetics, Pitié-Salpêtrière University Hospital, Paris, France; ICM, Institut du Cerveau et de la Moelle, INSERM U1127, CNRS UMR7225, Sorbonne Université, Paris, France.

Blair R Leavitt (BR)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada.

Raymund A C Roos (RAC)

Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands.

Peter Holmans (P)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.

Lesley Jones (L)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.

Douglas R Langbehn (DR)

Departments of Psychiatry and Biostatistics, University of Iowa, Iowa City, IA, USA.

Seung Kwak (S)

CHDI Management/CHDI Foundation, Princeton, NJ, USA.

Sarah J Tabrizi (SJ)

Huntington's Disease Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at UCL, London, UK.

Darren G Monckton (DG)

Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. Electronic address: darren.monckton@glasgow.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH